Ensuring the confidentiality of patient information obtained during a clinical trial of a medicinal product

O. Ponomarova
{"title":"Ensuring the confidentiality of patient information obtained during a clinical trial of a medicinal product","authors":"O. Ponomarova","doi":"10.33731/62021.249467","DOIUrl":null,"url":null,"abstract":"Keywords: clinical trial, confidential information, personal data, patient \nClinical trials are conductedin accordance with legal norms, subject to human rights and in accordance with internationalethical principles. Each clinical trial for the patient (subject) begins on a voluntarybasis and with acquaintance of the patient (subject) about the features of the study, itspurpose and purpose, explanation of possible risks, in addition, the patient is informedabout innovative drugs and access to free treatment during research. The patient participatesin the study of the drug of his own volition, signing a voluntary informed consent.It is important to ensure that the rights of the patient (subject) in the clinical trial of themedicinal product to privacy and the protection of personal data, which is confidential informationabout the person who is the subject of the study, are respected. During clinicaltrials, researchers and all persons involved in the research process should treat responsiblythe person participating in the study of the medicinal product as the object of study,namely with respect for the human right to privacy and its secrecy. Individuals and legalentities should be able to protect information legally under their control from disclosure,acquisition or use by others without their consent in a manner contrary to fair commercialpractice, if such information is confidential in the sense that it is as a whole or in theexact configuration and combination of its components, commonly known or available topersons in the circles normally involved with the information in question. It is importantto note that any information that becomes known about the patient (subject) during theclinical trial of the drug should be carefully protected by the party conducting the study.Therefore, it is important to note that the right of a patient not to disclose confidentialinformation about him is guaranteed by the Constitution of Ukraine. The right to medicalsecrecy is enshrined in the Law of Ukraine \"Fundamentals of Health Legislation\". Incases where the rights of the patient (subject) have been violated, the legislator providesfor criminal liability for intentional disclosure of medical secrets to a person who becameknown in connection with the performance of professional or official duties, if such an actcaused serious consequences and for illegal collection, storage, use, destruction, disseminationof confidential information about a person or illegal change of such informationcomes criminal liability.","PeriodicalId":356184,"journal":{"name":"Theory and Practice of Intellectual Property","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Theory and Practice of Intellectual Property","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33731/62021.249467","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Keywords: clinical trial, confidential information, personal data, patient Clinical trials are conductedin accordance with legal norms, subject to human rights and in accordance with internationalethical principles. Each clinical trial for the patient (subject) begins on a voluntarybasis and with acquaintance of the patient (subject) about the features of the study, itspurpose and purpose, explanation of possible risks, in addition, the patient is informedabout innovative drugs and access to free treatment during research. The patient participatesin the study of the drug of his own volition, signing a voluntary informed consent.It is important to ensure that the rights of the patient (subject) in the clinical trial of themedicinal product to privacy and the protection of personal data, which is confidential informationabout the person who is the subject of the study, are respected. During clinicaltrials, researchers and all persons involved in the research process should treat responsiblythe person participating in the study of the medicinal product as the object of study,namely with respect for the human right to privacy and its secrecy. Individuals and legalentities should be able to protect information legally under their control from disclosure,acquisition or use by others without their consent in a manner contrary to fair commercialpractice, if such information is confidential in the sense that it is as a whole or in theexact configuration and combination of its components, commonly known or available topersons in the circles normally involved with the information in question. It is importantto note that any information that becomes known about the patient (subject) during theclinical trial of the drug should be carefully protected by the party conducting the study.Therefore, it is important to note that the right of a patient not to disclose confidentialinformation about him is guaranteed by the Constitution of Ukraine. The right to medicalsecrecy is enshrined in the Law of Ukraine "Fundamentals of Health Legislation". Incases where the rights of the patient (subject) have been violated, the legislator providesfor criminal liability for intentional disclosure of medical secrets to a person who becameknown in connection with the performance of professional or official duties, if such an actcaused serious consequences and for illegal collection, storage, use, destruction, disseminationof confidential information about a person or illegal change of such informationcomes criminal liability.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
确保在药品临床试验期间获得的患者信息的保密性
关键字:临床试验,保密信息,个人数据,患者临床试验遵循法律规范,尊重人权,符合国际伦理原则。患者(受试者)的每一项临床试验都是在自愿的基础上开始的,并且患者(受试者)了解研究的特点、目的和目的、可能的风险的解释,此外,患者在研究期间被告知创新药物和获得免费治疗。患者自愿参与药物研究,签署一份自愿知情同意书。重要的是要确保患者(受试者)在药品临床试验中的隐私权和个人数据保护的权利得到尊重,这些个人数据是关于研究受试者的机密信息。在临床试验期间,研究人员和所有参与研究过程的人员应负责地将参与药物研究的人视为研究对象,即尊重隐私权及其保密权。个人和法律实体应该能够保护在其合法控制下的信息,使其不被他人未经其同意以违反公平商业惯例的方式披露、获取或使用,如果此类信息是机密的,则该信息是作为一个整体或其组成部分的确切配置和组合,通常与相关信息相关的圈子中的人员已知或可获得。重要的是要注意,在药物临床试验期间,任何关于患者(受试者)的信息都应由进行研究的一方仔细保护。因此,值得注意的是,乌克兰宪法保障了患者不披露其机密信息的权利。乌克兰《卫生立法基本原则》规定了医疗保密的权利。在患者(主体)权利受到侵犯的情况下,立法者规定,故意向因履行专业或公务而知悉的人泄露医疗秘密,如果这种行为造成严重后果,则追究刑事责任;非法收集、储存、使用、销毁、传播有关个人的机密信息或非法更改此类信息,则追究刑事责任。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Accelerated examination of patent applications for «green» technologies: foreign experience for Ukraine Draft Regulation of the European Union about artificial intelligence and related initiatives Intellectual property rights in the context of biology, medicine and pharmacy: a look into the future The sui generis right to non-original objects generated by a computer program: novelties of legal regulation ABUSE OF PATENTABILITY CRITERIA WHEN PATENTING INVENTIONS RELATED TO MEDICINES
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1